Eliem Therapeutics ELYM announced that it has completed a review of its business encompassing the status of its programs, resources and capabilities as part of its reorganization efforts. To this ...

SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of ...

Eliem Therapeutics announced Thursday that several members of its leadership team, including CEO Bob Azelby, are leaving the company and that it is slashing its workforce by 55%. The biotech is ...

For the biotech formerly known as Eliem Therapeutics, it’s all about the climb—Climb Bio, that is. Massachusetts-based Eliem unveiled a new corporate identity this week, announcing Wednesday that it ...

Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash ...

Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral radicular ...

Eliem Therapeutics, which is developing small-molecule drugs for neurological diseases, has raised $60 million in series B financing just 2 months after it formally launched with an $80 million series ...

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics (ELYM), Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies ...